Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,698 | -7,150 | -10,826 | -11,480 | -13,287 |
| Depreciation Amortization | 3 | 2 | 56 | 71 | 75 |
| Accounts payable and accrued liabilities | 183 | -404 | -122 | 496 | -445 |
| Other Working Capital | 235 | -138 | -536 | -1,256 | 990 |
| Other Operating Activity | 298 | 578 | 679 | 40 | 809 |
| Operating Cash Flow | $-7,979 | $-7,112 | $-10,749 | $-12,129 | $-11,858 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -12 | 8 | -5 | -121 | -51 |
| Investing Cash Flow | $-12 | $8 | $-5 | $-121 | $-51 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 23,670 | 4,002 | 7,452 | N/A | 21,723 |
| Common Stock Repurchased | N/A | -1 | -11 | N/A | N/A |
| Other Financing Activity | -30 | -5 | -28 | -26 | -1 |
| Financing Cash Flow | $23,640 | $3,996 | $7,413 | $-26 | $21,722 |
| Beginning Cash Position | 5,382 | 8,490 | 11,831 | 24,107 | 14,294 |
| End Cash Position | 21,031 | 5,382 | 8,490 | 11,831 | 24,107 |
| Net Cash Flow | $15,649 | $-3,108 | $-3,341 | $-12,276 | $9,813 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,979 | -7,112 | -10,749 | -12,129 | -11,858 |
| Capital Expenditure | -12 | -1 | -5 | -121 | -51 |
| Free Cash Flow | -7,991 | -7,113 | -10,754 | -12,250 | -11,909 |